DSC Investment Invests in Nucleix... "Cumulative Investment Exceeds 5.6 Billion KRW"
[Asia Economy Reporter Hyunseok Yoo] DSC Investment announced on the 16th that it has made an additional investment in the global bio-venture 'Nucleix'. With this funding round, DSC Investment's cumulative investment amount has surpassed $5 million (approximately 5.6 billion KRW).
Nucleix is a bio-venture based in Israel, established in 2008. It possesses a diagnostic platform technology that can more accurately detect early-stage cancer using biomarkers it has independently discovered. Utilizing this technology, the bladder cancer early diagnosis kit (Bladder EpiCheck) developed by Nucleix received CE certification in Europe in 2018 and is currently on sale. It is undergoing medical device approval certification in the United States and plans to start sales there within this year.
The company explained that Nucleix is especially recognized for having world-class technology in early lung cancer diagnosis. Nucleix's lung cancer early diagnosis kit (Lung EpiCheck) holds industry-leading accuracy in diagnosing stage 1 cancer.
This investment round, totaling approximately $55 million (about 61.6 billion KRW), involved many global investment firms. RA Capital, a bio-investment specialized venture capital (VC), led the investment, and BlackRock, the world's largest asset management company, was also listed among the investors. RA Capital, a Boston-based VC managing $4.6 billion, has previously invested in Moderna, Novavax, and Juno Therapeutics (acquired by Celgene). DSC Investment has shown steady trust and expectations for Nucleix by investing approximately 5.6 billion KRW over three rounds in three years since 2019.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
Based on this funding, Nucleix plans to accelerate research and development (R&D) of the lung cancer diagnostic kit and make a full-scale entry into the U.S., the world's largest medical market. Nucleix is currently developing an improved version of Lung EpiCheck and aims to begin pilot testing in 2022. In October last year, Nucleix published clinical data of the lung cancer diagnostic kit in the prestigious international journal, the European Respiratory Journal.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
